Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xencor, Inc.

http://www.xencor.com

Latest From Xencor, Inc.

EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody

If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.

Europe Approvals

Controversial Ginkgo Will Team With Persephone On Bacterial Delivery Of Microbial Therapies

Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.

Deals Business Strategies

Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf

AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.

Deal Watch Business Strategies

The Key To Big Pharma Deals: How Korea's ABL Reached $1bn Sanofi Agreement

ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.

South Korea Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register